Irwin Naturals Inc. (OTCQB:IWINF) (CSE:IWIN) (FRA:97X), has entered into a non-binding amended and restated letter of intent for a business combination with Braxia Scientific Corp.(OTCPK:BRAXF) (CSE:BRAX) (FWB:4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares of Braxia.

Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia share based upon a valuation of the outstanding Braxia shares of $30 million...